Literature DB >> 22084346

Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia.

James G Taylor, Deepika S Darbari, Deepika S Darari, Irina Maric, Zachariah McIver, Diane C Arthur.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22084346      PMCID： PMC3508679          DOI： 10.7326/0003-4819-155-10-201111150-00024

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  5 in total

1.  Malignancies in sickle cell disease patients treated with hydroxyurea.

Authors:  Alina Ferster; Eric Sariban; Nathalie Meuleman
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

Review 2.  Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.

Authors:  Jean-Jacques Kiladjian; Jean-Didier Rain; Jean-Francois Bernard; Jean Briere; Christine Chomienne; Pierre Fenaux
Journal:  Semin Thromb Hemost       Date:  2006-06       Impact factor: 4.180

3.  The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

Authors:  Martin H Steinberg; William F McCarthy; Oswaldo Castro; Samir K Ballas; F Danny Armstrong; Wally Smith; Kenneth Ataga; Paul Swerdlow; Abdullah Kutlar; Laura DeCastro; Myron A Waclawiw
Journal:  Am J Hematol       Date:  2010-06       Impact factor: 10.047

Review 4.  Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.

Authors:  Sophie Lanzkron; John J Strouse; Renee Wilson; Mary Catherine Beach; Carlton Haywood; HaeSong Park; Catherine Witkop; Eric B Bass; Jodi B Segal
Journal:  Ann Intern Med       Date:  2008-05-05       Impact factor: 25.391

Review 5.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113
  5 in total
  6 in total

1.  Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient.

Authors:  Samuel Regan; Xuebin Yang; Niklas K Finnberg; Wafik S El-Deiry; Jeffrey J Pu
Journal:  Cancer Biol Ther       Date:  2019-08-18       Impact factor: 4.742

Review 2.  Update on the use of hydroxyurea therapy in sickle cell disease.

Authors:  Trisha E Wong; Amanda M Brandow; Wendy Lim; Richard Lottenberg
Journal:  Blood       Date:  2014-10-06       Impact factor: 22.113

3.  Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation.

Authors:  Jack Y Ghannam; Xin Xu; Irina Maric; Laura Dillon; Yuesheng Li; Matthew M Hsieh; Christopher S Hourigan; Courtney D Fitzhugh
Journal:  Blood       Date:  2020-04-02       Impact factor: 22.113

4.  Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.

Authors:  Javier Bolaños-Meade; Kenneth R Cooke; Christopher J Gamper; Syed Abbas Ali; Richard F Ambinder; Ivan M Borrello; Ephraim J Fuchs; Douglas E Gladstone; Christian B Gocke; Carol Ann Huff; Leo Luznik; Lode J Swinnen; Heather J Symons; Stephanie A Terezakis; Nina Wagner-Johnston; Richard J Jones; Robert A Brodsky
Journal:  Lancet Haematol       Date:  2019-03-14       Impact factor: 18.959

5.  Pure Erythroid Leukemia in a Sickle Cell Patient Treated with Hydroxyurea.

Authors:  Dhiraj Kumar Yadav; Thushara Paul; Mohamed Alhamar; Kedar Inamdar; Yue Guo
Journal:  Case Rep Oncol       Date:  2020-07-16

6.  Acute leukemia in sickle cell disease patients in a tertiary health facility in Nigeria: a case series.

Authors:  Oladapo W Aworanti; Foluke A Fasola; Taiwo R Kotila; John A Olaniyi; Biobele J Brown
Journal:  Afr Health Sci       Date:  2020-09       Impact factor: 0.927
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.